COMPUGEN Business Summary

Compugen Ltd. (CGEN) is a clinical-stage biotechnology firm that leverages its proprietary AI/ML-powered discovery engine, Unicigen, to identify novel immuno-oncology targets and biological pathways. The company operates through a high-leverage business model focused on strategic R&D collaborations and licensing, generating revenue via upfront payments, milestone-based fees, and tiered royalties. Its primary business segments revolve around the development of first-in-class monoclonal and bispecific antibodies, most notably the PVRIG inhibitor COM701 and the IL-18 binding protein inhibitor GS-0321 (licensed to Gilead Sciences). Compugen competes directly with immuno-oncology specialists such as Agenus, iTeos Therapeutics, and Arcus Biosciences, distinguishing itself as a specialized 'target discovery engine' that de-risks novel biology for late-stage pharmaceutical partners like AstraZeneca and Gilead. The company’s leadership underwent a strategic transition in September 2025, with Dr. Eran Ophir, the former scientific lead, ascending to President and CEO, while long-time CEO Dr. Anat Cohen-Dayag transitioned to Executive Chair. The executive suite is supported by CFO David Silberman, a veteran of Oramed Pharmaceuticals, and Chief Medical Officer Dr. Michelle Mahler. Compugen was co-founded in 1993 by Eli Mintz, Simchon Faigler, and Amir Natan, who were among the first to apply computational algorithms to genomic and proteomic data. Notable institutional and strategic backing includes Gilead Sciences and AstraZeneca, alongside board oversight from industry experts such as Michele Holcomb, reflecting a robust pedigree in both computational biology and clinical execution.